908 Devices Receives $7 Million in Series B Funding
News Sep 11, 2013
908 Devices' funding includes new investment from Schlumberger and follow-on investments from ARCH Venture Partners, Razor’s Edge Ventures and University of Tokyo Edge Capital (UTEC). In addition, 908 Devices and Schlumberger signed a technical collaboration and development agreement to apply 908 Devices’ technology to a number of applications in the oil and gas industry. 908 Devices expects this multi-year agreement to bring both development and product revenues to the company.
“These latest investments are a strong validation that High Pressure Mass Spec (HPMS) is a true platform with transformative impact across chemical analysis,” said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. “Many of the new capabilities produced under our development agreement will also benefit our core safety and security customers and at the same time it opens an exciting new market for us. We could not ask for a better collaborator than Schlumberger, the world leader in oil and gas services, whose capabilities and technical know-how are unparalleled.”
With High Pressure Mass Spectrometry (HPMSTM), 908 Devices is producing simple and purpose-built, battery-powered tools untethered from permanent facilities or mobile laboratories. Truly handheld, weighing only a few pounds and extremely rugged, these analyzers are far beyond the complex ‘luggable’ systems available today. These systems give non-specialist field personnel analysis with extreme sensitivity – to the part-per-billion level – while simultaneously distinguishing hundreds of different chemicals.
UK Not Ready for Brexit’s Impact on Food, Report WarnsNews
Severe problems with the UK food system are likely unless issues are addressed, according to latest expert reportREAD MORE
High Serum Serotonin Levels Found in Blood of SIDS InfantsNews
Findings from NIH-funded study could provide basis for forensic SIDS test.READ MORE
Advanced Cancer Drug Study Highlights Need for Novel ApproachesNews
The pre-clinical findings, just published in Cell Chemical Biology, may lay the foundation for improving therapies for treatment-resistant, aggressive prostate cancer.READ MORE
Comments | 0 ADD COMMENT
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017
8th Edition of International Conference on Mass Spectromerty
Mar 12 - Mar 13, 2018